Key facts
- ORTHOSON’s last known valuation is $31.0M (Oct 2025).
- It has raised $18.9M; the latest was Later Stage VC ($3.5M) in Oct 2025.
- Notable investors include Innovate UK, University of Oxford, Yonghua Capital, Perivoli Innovations, Anjost Investment — 12 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 12 names
- ·Watchlist + deal alerts for ORTHOSON
- ·The full record, as it builds
Funding rounds
No funding rounds for ORTHOSON are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About ORTHOSON
Developer of an injectable bio-structural gel implant system designed to restore disc function and relieve back pain from degeneration. The company offers a micro-invasive implant that is injected into the disc, forms a supportive scaffold, restores mechanical properties, and suppresses degeneration, enabling patients with degenerative disc disease to achieve pain relief and improved spinal stability.
- Sector
- Healthcare
- HQ
- Oxford, United Kingdom
- Founded
- 2015
- Employees
- 14
- Website
- orthoson.com/
- Ownership
- Privately Held (backing)
ORTHOSON doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in ORTHOSON shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on ORTHOSON in its N-PORT filings yet. We sweep new filings monthly.